Valneva SE announced on August 18, 2025, that Health Canada granted marketing authorization for its single-dose chikungunya vaccine, IXCHIQ®, for individuals aged 12 years and older. This approval adds to the existing adult marketing authorization in Canada and complements the adolescent label extension received in Europe in April 2025.
The label extension application to Health Canada included positive six-month adolescent Phase 3 data, which demonstrated a high and sustained immune response in 99.1% of adolescents, and that the vaccine was generally well tolerated. It also included antibody persistence data showing the immune response was sustained for 24 months in 97% of participants.
This approval is a major milestone for IXCHIQ®, as chikungunya continues to pose a significant risk to people in or traveling to endemic regions. Expanding access to all age groups is crucial for providing protection and mitigating the burden of this debilitating illness, which is spreading into previously unaffected areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.